EUVIMEDEUVIMED entdecken
Crossref

Cost‐Effectiveness of Antiviral Therapy in Patients With High Viremic Indeterminate Phase Chronic Hepatitis B

Suk-Chan Jang iD, Won-Mook Choi iD, Gi-Ae Kim iD, Gwang Hyeon Choi iD, Yun Bin Lee, Dong Hyun Sinn, Hye-Lin Kim iD, Young-Suk Lim iD

Liver International · 2025

DOI: 10.1111/liv.70238 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Liver International, 2025. Verfasst von Suk-Chan Jang und 7 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, Sungkyunkwan University, Suwon, Gyeonggi-do, Korea. Hauptthemen laut MEDLINE: Antiviral Agents, Hepatitis B, Chronic, Viremia. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 48 Literaturangaben. Gefördert von: Patient-Centered Clinical Research Coordinating Center, National Evidence-based Healthcare Collaborating Agency, National Cancer Center.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background & Aims Growing evidence suggests that chronic hepatitis B (CHB) patients with high viremia are at a high risk of developing hepatocellular carcinoma (HCC) even with normal alanine transaminase (ALT) levels. This study aimed to evaluate the cost‐effectiveness of initiating antiviral therapy in patients in an indeterminate phase of CHB, defined as those who do not clearly fit into the established four phases categorised by serum HBV DNA and ALT levels.

Methods

A cost‐utility analysis was conducted using a Markov model to compare the incremental cost‐effectiveness ratio (ICER) of initiating antiviral therapy at the indeterminate phase (‘treat‐Indet’) versus delaying treatment until chronic hepatitis (‘untreated‐Indet’). A hypothetical cohort of 10 000 patients in the indeterminate phase (60% male, HBV DNA 4–8 log 10 IU/mL, ALT < 40 IU/L, 50% HBeAg‐positivity) was simulated over a 10‐year horizon. Input parameters were obtained from a Korean multicentre historical cohort.

Results

From a healthcare system perspective, the ICER of the treat‐Indet strategy was US$12050/quality‐adjusted life‐year (QALY), indicating cost‐effectiveness under the local willingness‐to‐pay threshold of US$25000/QALY. From a societal perspective, the ICER was less than 0, indicating lower costs. A U‐shaped association was identified between baseline HBV DNA levels and the ICER, as HBV DNA levels of 6–7 log 10 IU/mL were associated with the lowest ICER (US$2018/QALY), followed by 5–6 (US$7233/QALY), 7–8 (US$19677/QALY) and 4–5 log 10 IU/mL (US$24570/QALY), following the order of HCC risk.

Conclusions

Initiating antiviral therapy in high‐viremic indeterminate phase CHB patients with normal ALT levels was cost‐effective compared with delaying treatment until chronic hepatitis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antiviral AgentsHepatitis B, ChronicViremiaHumansCost-Benefit AnalysisMaleMarkov ChainsFemaleDNA, ViralAlanine TransaminaseQuality-Adjusted Life YearsCarcinoma, HepatocellularLiver NeoplasmsRepublic of KoreaMiddle AgedHepatitis B virusAdultHepatitis B e Antigens

Stichwörter der Autor:innen

HBV DNAgrey zoneliver cancernucleos(t)ide analoguesprevention

Substanzen

Antiviral AgentsDNA, ViralAlanine TransaminaseHepatitis B e Antigens

Autor:innen und Institutionen

  • School of Pharmacy, Sungkyunkwan University, Suwon, Gyeonggi-do, Korea.
  • Department of Gastroenterology, Liver Center, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
  • Department of Internal Medicine, Kyung Hee University School of Medicine, Seoul, Korea.
  • Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam-si, Gyeonggi-do, Korea.
  • Department of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine, Seoul, Korea.
  • Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.

ORCID-Profile: Suk-Chan Jang, Won-Mook Choi, Gi-Ae Kim, Gwang Hyeon Choi, Hye-Lin Kim, Young-Suk Lim

Förderung

  • Patient-Centered Clinical Research Coordinating Center
  • National Evidence-based Healthcare Collaborating Agency
  • National Cancer Center

Zitieren

APA

Jang, S. C., Choi, W. M., Kim, G. A., Choi, G. H., Lee, Y. B., Sinn, D. H., Kim, H. L., & Lim, Y. S. (2025). Cost‐Effectiveness of Antiviral Therapy in Patients With High Viremic Indeterminate Phase Chronic Hepatitis B. Liver International. https://doi.org/10.1111/liv.70238

Vancouver

Jang SC, Choi WM, Kim GA, Choi GH, Lee YB, Sinn DH, et al. Cost‐Effectiveness of Antiviral Therapy in Patients With High Viremic Indeterminate Phase Chronic Hepatitis B. Liver International. 2025. doi:10.1111/liv.70238

BibTeX
@article{Jang2025,
  author = {Jang, Suk-Chan and Choi, Won-Mook and Kim, Gi-Ae and Choi, Gwang Hyeon and Lee, Yun Bin and Sinn, Dong Hyun and Kim, Hye-Lin and Lim, Young-Suk},
  title = {Cost‐Effectiveness of Antiviral Therapy in Patients With High Viremic Indeterminate Phase Chronic Hepatitis B},
  journal = {Liver International},
  year = {2025},
  doi = {10.1111/liv.70238}
}
Kostenlos starten →